This is the first report of the efficacy of leukocytapheresis (LCAP) in a patient with refractory adult onset Still's disease (AOSD) during pregnancy. A 32-year-old Chinese pregnant woman with AOSD who had been treated with prednisolone failed to achieve disease stabilization. The patient's disease was successfully controlled with the initiation of LCAP. Subsequently, she gave birth via Caesarean section to a 1,878 g baby boy at 34 weeks of gestation while maintaining remission. We conclude that LCAP is an alternative treatment in pregnant patients with refractory AOSD, particularly in those concerned about potential teratogenic and other adverse effects.
Introduction
Adult onset Still's disease (AOSD), first described by Bywaters in 1971 (1) , is a systemic inflammatory disorder of unknown etiology. AOSD is uncommon, with an estimated prevalence of less than one case per 100,000 people, and predominantly affects young adults. The concomitant occurrence of pregnancy and AOSD is rare, and little is known about the effects of pregnancy on the disease course and maternal-fetal outcomes in patients with AOSD. Treatment comprises nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs) and immunosuppressive agents. The selection of multidrug treatment depends on the phase of the disease and extent of organ involvement. The therapeutic approach to treating refractory AOSD complicated by pregnancy is likely to differ from that typically used to treat the disease. Such differences are modified by clinical tolerance of the disease and the toxic effects of the drugs on both the mother and child. Izumi et al. (2) reported the case of a refractory AOSD patient who was safely and effectively treated with leukocytapheresis (LCAP), which employs a filter designed to remove leukocytes and monocytes. We herein report the efficacy of LCAP in combination with steroids in a patient with refractory AOSD during pregnancy.
Case Report
A 32-year-old woman was admitted to our hospital due to a fever, rash, lymphadenopathy, polyarthritis and sore throat. She had been doing well until nine days before admission, when she developed a sore throat. Four days before admission, fever spikes of 39 , cervical lymphadenopathy and swelling of the wrist and ankle joints were noted. The patient consulted her physician, who prescribed cefcapene pivoxil, dextromethorphan hydrobromide, tipepidine and PA, the generic ingredients of which include salicylamide, promethazine methylene disalicylate and caffeine. However, the patient's symptoms did not improve, and she was admitted to our hospital during the 14th week of pregnancy.
The patient had been previously healthy, took no medications and had no known allergies. She did not smoke, drink alcohol or use illicit drugs. She had been born in China.
She was 157 cm tall and weighed 48.0 kg. A clinical examination confirmed a temperature of 38.0 , blood pressure of 110/70 mmHg and regular pulse of 121 beats per minute. Palpable lymph nodes were detected in the anterior cervical regions, with exudate adenopathy and a rash (Fig. 1) ; the remainder of the examination was normal. No splenomegaly or hepatomegaly was detected. The laboratory results showed the following (Table) : white blood cell (WBC) count of 24,310/mm 3 with 94.5% neutrophils, the Creactive protein (CRP) concentration was 16.5 mg/dL, the erythrocyte sedimentation rate was 137 mm in the first hour, the aspartate aminotransferase (AST) level was 53 IU/L, alanine transferase (ALT) was 35 IU/L, lactate dehydrogenase (LDH) was 396 IU/L, rheumatoid factor (RF) was 1 U/ mL, and antinuclear antibody (ANA) was negative. In addition, blood and urine cultures were negative, as were serologic tests for viral infections, such as Epstein-Barr virus (EBV), human T-cell leukemia virus type 1 (HTLV-1), hepatitis C viruses, parvovirus B19, human immunodeficiency virus and cytomegalovirus (CMV). Chemiluminescent immunoassays for hepatitis B virus (HBV)-related serum markers were negative for hepatitis B surface antigen (HBsAg), HBeAg and anti-HBe and positive for antihepatitis B surface antibody (HBsAb) and anti-hepatitis B core antibody (HBcAb). Furthermore, the HBV DNA titer was undetectable (<10^3 copies/mL); however, an elevated serum ferritin level of 2,920.9 ng/mL was observed.
A diagnosis of AOSD was strongly suggested based on the high fever, arthralgia, rashes, sore throat, lymphadenopathy, leukocytosis, liver functional disorder and negative RF and ANA results. There was no evidence of infection or malignancy. The patient was given a diagnosis of AOSD based on the criteria proposed by Yamaguchi et al. (3) . As treatment with ibuprofen was ineffective, prednisolone (PSL) therapy was initiated at a dose of 25 mg daily. However, AOSD was considered to be resistant to treatment. Therefore, the patient was given high-dose PSL (50 mg/day); however, her symptoms did not improve. She declined any further increases in the dose of PSL beyond 50 mg, as well as additional immunosuppressive therapy, due to anxiety related to potential fetal abnormalities. LCAP was then chosen as an alternative therapy. The LCAP treatment, which employs extracorporeal circulation therapy using a fiber filter, was administered twice a week for 12 weeks, without changing the doses of the other drugs. A total of 3.0 L of blood was filtered via a fine fiber (CS-100, Cellsorba, Asahi Kasei Medical, Tokyo, Japan) at a blood flow rate of 50 mL/min for 60 minutes. Heparin was used as an anticoagulant. Access was obtained via the cubital vein, and the processed blood was returned to the contralateral vein. The patient underwent a total of 31 LCAP procedures prior to delivery, with no adverse events except for mild anemia. Consequently, her symptoms, i.e., spiking fevers and arthralgia, gradually improved, and the elevated levels of ferritin, tumor necrosis factor (TNF)-α and interleukin (IL)-18, monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2), macrophage inflammatory protein-1 alpha (MIP-1α)/CCL3, IL-8/chemokine (C-X-C motif) ligand 8 (CXCL8) and interferon-gamma-inducible protein 10 (IP-10)/CXCL10 decreased (Fig. 2 ). The dose of PSL was then reduced to 20 mg following the resolution of the patient's symptoms. Six weeks later, the patient was discharged from the hospital. The dose of PSL was gradually decreased to 15 mg/day and continued until the child was delivered in order to avoid disease exacerbation. Due to a premature rupture of the membranes, a Cesarean section was performed on the 34th week of pregnancy, resulting in the birth of a healthy 1,878 g boy. No flare-ups were observed during the postpartum period. The LCAP treatment was progressively tapered, and the dose of PSL was gradually decreased to 5 mg/day. The patient's clinical course remained unchanged over the subsequent six months of follow-up.
Discussion
The most commonly used treatment for AOSD is corticosteroid therapy. These agents can be used to safely control active AOSD during pregnancy. The present patient, however, was corticosteroid-resistant and exhibited recurrence of active disease under high-dose corticosteroid therapy. We agreed with the patient in her desire to receive alternative conservative treatment to avoid increasing the dose of corticosteroids. Conventional DMARDs and biologics, such as TNF-α inhibitors and IL-1 and IL-6 blockers, are often used to treat patients with AOSD refractory to conventional treatment or those with life-threatening manifestations aiming for better disease control (4) . DMARDs applied in the setting of AOSD include methotrexate, cyclosporine, azathioprine, cyclophosphamide and leflunomide. Currently, only limited data exist to support the use of any particular DMARD, and no controlled trials have assessed the efficacy of these agents in patients with AOSD. Furthermore, experience with TNF-α inhibitors in AOSD patients remains limited to case reports and small case series (5-7). The IL-1 receptor antagonist anakinra has emerged as a promising new therapeutic option for refractory AOSD (8) . However, anakinra has not yet become routinely available in Japan. Tocilizumab is another potential therapeutic option (9); however, its efficacy is not established for AOSD, as the induction of treatmentrelated macrophage activation syndrome (MAS) was reported in an AOSD patient treated with tocilizumab (10). The use of cytotoxic agents during pregnancy may be unavoidable to ensure maternal survival, despite the dangers to the developing fetus. There are differences in the transplacental passage of TNF inhibitors. For example, such passage is most extensive for monoclonal antibodies (e.g., infliximab, adalimumab, golimumab), with less frequent passage observed for fusion proteins (e.g., etanercept). Monoclonal antibodies display increasing transplacental passage during pregnancy, with concentrations in the cord blood similar to or higher than the maternal levels observed at term. In contrast, TNF inhibitors appear to not be strong human teratogens, although the long-term effects in children exposed to these drugs are unknown at present. The very limited experience with tocilizumab and anakinra treatment during pregnancy prevents any conclusions on their compatibility in pregnant patients.
Patients with occult or resolved hepatitis B receiving chemotherapy or immunosuppression are potentially at risk of HBV reactivation, which can be disastrous as it can result in acute liver failure and death. In patients with rheumatologic diseases, the incidence of HBV reactivation among those with resolved infection is rather low, ranging from 2.2 to 5.2% (11, 12) . However, in a later study, when only the patients treated with biological agents were taken into account, the incidence increased to 11.5% (13). Furthermore, virus To the best of our knowledge, there are no current reports regarding HBV reactivation during treatment with LCAP. AOSD is a systemic inflammatory disorder characterized by a high spiking fever, transient skin rash, polyarthralgia and hyperferritinemia. While its pathogenesis remains to be clarified, leukocytosis is an important diagnostic criterion. Activated leukocytes are known to produce an array of pleiotropic cytokines that can exacerbate and perpetuate inflammation. Several cytokines have been implicated in the pathogenesis of AOSD. Some cytokines, including TNF-α, IL-6 and interferon-γ, have been detected at high levels in the sera of patients with AOSD. However, the roles of chemokines in the onset of AOSD and the pathogenesis at different stages of the disease remain unclear. Kasama et al. (14) demonstrated elevated serum levels of several groups of chemokines, including CXC-and CC-chemokines, in patients with active AOSD compared with that observed in healthy subjects. LCAP has also recently been used to induce remission in AOSD patients who fail to respond to cor-ticosteroids. However, the mechanisms by which LCAP induces clinical remission remain unknown. The mechanism of LCAP in inflammatory disease is speculated to involve the removal of activated leukocytes and inflammatory cytokines and induction of anti-inflammatory cytokines (15) (16) (17) . The WBC count and serum levels of TNF-α, IL-18, MCP-1/CCL2, MIP-1α/CCL3, IL-8/CXCL8 and IP-10/CXCL10 are reduced after LCAP treatment. These findings suggest that highly safe LCAP treatment can be used to remove activated leukocytes, cytokines and chemokines. Several studies have further demonstrated that dysregulated or increased levels of cytokines, such as IL-6 and IL-18, in the acute phase of AOSD correlate with the disease activity (18, 19) . In the present case, the elevated serum levels of IL-18 were observed to decrease after LCAP treatment. Kasama et al. (14) demonstrated that no significant differences in the course of the changes in the serum levels of IL-8, IP-10, MIP-1a and MCP-1 were observed among the medications. Similar results were observed in the present case.
Intensive LCAP treatment appeared to be effective for induction therapy. We scheduled the LCAP treatment twice a week for twelve weeks until the dose of prednisolone was 20 mg. Subsequently, the LCAP treatment was tapered to once a week for four weeks and further tapered to once every two weeks for six weeks. LCAP has been found to provide clinical benefits in patients with refractory rheumatoid arthritis (RA) and ulcerative colitis (UC). Patients with RA and UC typically receive treatment every week. In contrast, Sakuraba et al. (20) showed that intensive leukocyte removal therapy (LRT), at two treatments per week, in patients with active UC was more efficacious than weekly LRT and did not increase the incidence of side effects. This study supports the notion that the efficacy of LRT is frequency-dependent. Depleting excess and activated leukocytes by intensive LCAP treatment may alleviate inflammation and promote the remission of AOSD. The LCAP treatment corrected the Th1/Th2 cytokine balance in the patients with RA (15, 21) . Maternal tolerance toward fetal alloantigens is explained by predominant Th2-type immunity during pregnancy. Our findings therefore suggest that the AOSD patients produced inflammatory cytokines with predominant Th1-type immunity, and intensive LCAP treatment corrected the Th1/Th2 cytokine balance, thus resulting in the induction of tolerance. IL-8 plays an important role in pregnancy and promotes neutrophil recruitment and angiogensesis (22, 23) . Elevated levels of IL-8 in the cervical fluid and serum were found to be correlated with threatened premature delivery. Intensive LCAP treatment reduced the serum levels of IL-8, which could have contributed to the maintenance of pregnancy in our case. In the present report, we also demonstrated that the LCAP treatment is not only helpful for improving AOSD refractory to conventional treatment, but can also induce remission.
LCAP requires no addition of potentially toxic drugs. LCAP has been performed in pregnant patients with chronic myeloid leukemia (24) , RA (25) and UC (26, 27) , demonstrating its safety for both mothers and fetuses. However, LCAP can result in anemia. Indeed, our patient developed mild anemia after several weeks of LCAP treatment. Her hematocrit level exhibited a slow but persistent decline from a pre-LCAP value of 29 to 21% after the 12th cycle of LCAP. As the patient did not require a blood transfusion, she was administered an iron preparation and no other complications were observed.
Since this is only a case report, further studies involving a larger number of patients are required to certify the safety and efficacy of LCAP in patients with active AOSD during pregnancy.
Our experience suggests that LCAP is a viable alternative to cytotoxic agents, TNF-α inhibitors and tocilizumab for the treatment of AOSD. During pregnancy, AOSD can potentially be managed with LCAP until delivery, at which time more aggressive therapies can be safely initiated.
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